[go: up one dir, main page]

MX2017005126A - Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal. - Google Patents

Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal.

Info

Publication number
MX2017005126A
MX2017005126A MX2017005126A MX2017005126A MX2017005126A MX 2017005126 A MX2017005126 A MX 2017005126A MX 2017005126 A MX2017005126 A MX 2017005126A MX 2017005126 A MX2017005126 A MX 2017005126A MX 2017005126 A MX2017005126 A MX 2017005126A
Authority
MX
Mexico
Prior art keywords
renal
compositions
methods
forecast
diagnosis
Prior art date
Application number
MX2017005126A
Other languages
English (en)
Other versions
MX388231B (es
Inventor
Joseph Anderberg
Jeff Gray
Kevin Nakamura
Paul Mcpherson
James Patrick Kampf
Thomas Kwan
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2017005126A publication Critical patent/MX2017005126A/es
Publication of MX388231B publication Critical patent/MX388231B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para controlar, diagnosticar, pronosticar y determinar los regímenes de tratamiento en sujetos que padecen de o que se sospecha que tienen lesión renal. En particular, la lesión se refiere al uso de ensayos que detectan uno o más de motivo C-C de quimiocina 16, motivo C-C de quimiocina 14, y receptor de proteína cinasa tirosina UFO como ensayos de biomarcador de diagnóstico y pronóstico en lesiones renales.
MX2017005126A 2014-10-20 2015-10-20 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal. MX388231B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462066316P 2014-10-20 2014-10-20
US201462066310P 2014-10-20 2014-10-20
US201462066313P 2014-10-20 2014-10-20
PCT/US2015/056462 WO2016064877A2 (en) 2014-10-20 2015-10-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (2)

Publication Number Publication Date
MX2017005126A true MX2017005126A (es) 2017-09-15
MX388231B MX388231B (es) 2025-03-19

Family

ID=55761743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005126A MX388231B (es) 2014-10-20 2015-10-20 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.

Country Status (13)

Country Link
US (2) US11333671B2 (es)
EP (2) EP3210018B1 (es)
JP (4) JP6792553B2 (es)
KR (1) KR102431003B1 (es)
CN (2) CN107003301B (es)
AU (2) AU2015336069B2 (es)
BR (1) BR112017008218A2 (es)
CA (1) CA2965153C (es)
EA (1) EA201790696A1 (es)
ES (1) ES2907551T3 (es)
MX (1) MX388231B (es)
PT (1) PT3210018T (es)
WO (1) WO2016064877A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3210018T (pt) 2014-10-20 2021-10-04 Astute Medical Inc Métodos e composições para o diagnóstico e prognóstico de lesão renal e insuficiência renal
MX2019008260A (es) 2017-01-12 2020-01-27 Astute Medical Inc Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3732196A4 (en) 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
JP7221985B2 (ja) * 2018-04-02 2023-02-14 ポトレロ メディカル，インコーポレイテッド 体液の排出および分析、並びに健康の評価のためのシステム
US12114978B2 (en) 2018-04-02 2024-10-15 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids and assessing health
WO2020243011A1 (en) * 2019-05-24 2020-12-03 Astute Medical, Inc. Methods for evaluation and treatment of renal injury based on c-c motif chemokine ligand 14 measurement
US20230290457A1 (en) * 2020-03-23 2023-09-14 Biocogniv Inc. Artificial intelligence medical device
GB2596142B (en) * 2020-06-19 2023-11-29 Secr Defence Methods and associated uses, kits and systems for assessing sepsis
CA3202228A1 (en) * 2020-11-18 2022-05-27 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
FI934437L (fi) 1991-04-10 1993-11-22 Biosite Diagnostics Inc Crosstalk-inhibitorer och deras anvaendning
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20030157573A1 (en) 2002-02-12 2003-08-21 Orna Mor Use of Axl receptor for diagnosis and treatment of renal disease
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
CA2614935A1 (en) 2005-07-21 2007-02-01 The Johns Hopkins University Methods of detecting and treating acute kidney injury
EP1996013A4 (en) 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
US20090226435A1 (en) 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
CN102246038B (zh) * 2008-10-21 2014-06-18 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2462438A4 (en) 2009-08-07 2013-01-23 Rules Based Medicine Inc METHODS AND DEVICES FOR DETECTING REJECTION OF RENAL TRANSPLANT
NZ599105A (en) 2009-09-21 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104793000A (zh) 2009-11-07 2015-07-22 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
EA201290195A1 (ru) 2009-11-07 2012-12-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290387A1 (ru) 2009-12-20 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT2666872T (pt) 2010-02-05 2016-07-08 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2585827A4 (en) * 2010-06-23 2013-12-04 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
CN105137085A (zh) * 2010-06-23 2015-12-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012136548A1 (en) 2011-04-04 2012-10-11 Universiteit Gent Biomarkers for acute kidney injury
WO2013043310A1 (en) 2011-08-26 2013-03-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2788759B1 (en) * 2011-12-08 2019-02-20 Astute Medical, Inc. Methods and uses for diagnosis of renal injury and renal failure
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
EP2962109A4 (en) 2013-02-26 2016-12-07 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
PT3210018T (pt) 2014-10-20 2021-10-04 Astute Medical Inc Métodos e composições para o diagnóstico e prognóstico de lesão renal e insuficiência renal

Also Published As

Publication number Publication date
JP2022046669A (ja) 2022-03-23
AU2015336069B2 (en) 2021-11-25
US20180209990A1 (en) 2018-07-26
AU2015336069A1 (en) 2017-05-25
US12099067B2 (en) 2024-09-24
EP3210018A2 (en) 2017-08-30
JP7002623B2 (ja) 2022-02-10
CN110702921A (zh) 2020-01-17
JP7217796B2 (ja) 2023-02-03
AU2022201130A1 (en) 2022-03-17
JP2023052587A (ja) 2023-04-11
AU2022201130B2 (en) 2024-06-27
CN107003301A (zh) 2017-08-01
CN110702921B (zh) 2024-02-06
KR20170084102A (ko) 2017-07-19
JP6792553B2 (ja) 2020-11-25
US11333671B2 (en) 2022-05-17
WO2016064877A3 (en) 2016-09-09
PT3210018T (pt) 2021-10-04
EP3210018B1 (en) 2021-07-28
CN107003301B (zh) 2019-11-01
JP2017533427A (ja) 2017-11-09
EP3968022A1 (en) 2022-03-16
EP3210018A4 (en) 2018-06-20
KR102431003B1 (ko) 2022-08-09
EA201790696A1 (ru) 2017-10-31
BR112017008218A2 (pt) 2018-01-09
WO2016064877A2 (en) 2016-04-28
CA2965153C (en) 2023-10-24
JP2021039112A (ja) 2021-03-11
CA2965153A1 (en) 2016-04-28
ES2907551T3 (es) 2022-04-25
US20220236286A1 (en) 2022-07-28
MX388231B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
MX2017005126A (es) Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
IL280634A (en) Diagnostic assays and kits for detection of folate receptor 1
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
MX341191B (es) Metodos y composiciones para diagnostico y prognosis de lesion renal y falla renal.
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX383381B (es) Métodos y composiciones para detectar proteínas mal plegadas.
CR20130657A (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
AR088083A1 (es) USO DE ANTICUERPOS DE UNION A IL-1b
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX386919B (es) Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
WO2015164747A8 (en) Methods for diagnosing celiac disease using circulating cytokines/chemokines
MX362049B (es) Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
MX2019008260A (es) Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
MX395376B (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.